Condition: Psoriasis · Sponsor: Bausch Health Americas, Inc.
This study is to evaluate the safety, the systemic exposure of halobetasol propionate (HP), and the hypothalamic-pituitary-adrenal (HPA) axis suppression potential for topically applied IDP-122 lotion in pediatric participants with moderate to severe plaque psoriasis.
This description comes directly from the study's public registry record.
Alison Magnotti-Nagel · 9085418664 · alison.magnotti-nagel@bauschhealth.com
Always discuss trial participation with your own doctor first.
| Bausch Site 11 | Fountain Valley, California, United States | Terminated |
| Bausch Site 2 | Thousand Oaks, California, United States | Recruiting |
| Bausch Site 07 | Doral, Florida, United States | Recruiting |
| Bausch Site 3 | Miami, Florida, United States | Recruiting |
| Bausch Site 06 | Miami, Florida, United States | Terminated |
| Bausch Site 05 | Spartanburg, South Carolina, United States | Terminated |
| Bausch Site 1 | Spokane, Washington, United States | Terminated |
| Bausch Site 12 | Santo Domingo, Dominican Republic | Recruiting |
| Bausch Site 4 | Panama City, Panama | Terminated |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03987763